Published in Am J Gastroenterol on June 01, 2005
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Cancer in inflammatory bowel disease. World J Gastroenterol (2008) 2.12
Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol (2008) 1.79
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol (2012) 1.63
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42
Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol (2008) 1.30
Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J Gastroenterol (2009) 1.24
Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res (2011) 1.21
Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol (2013) 1.17
Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol (2014) 1.16
Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology (2009) 1.15
The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag (2007) 1.12
Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis (2009) 1.10
Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity. Gut Microbes (2012) 1.09
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis. Carcinogenesis (2010) 1.04
Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer (2012) 1.00
Ulcerative colitis-associated colorectal cancer. World J Gastroenterol (2014) 0.97
Colon cancer screening and surveillance in inflammatory bowel disease. Clin Endosc (2014) 0.95
Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol (2012) 0.95
Inflammatory Bowel Disease-related Colorectal Cancer in the Asia-Pacific Region: Past, Present, and Future. Intest Res (2014) 0.93
Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol (2010) 0.92
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci (2013) 0.92
Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol (2009) 0.91
Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol (2014) 0.91
Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis (2010) 0.89
Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol (2012) 0.88
Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol (2013) 0.88
The risk of colorectal cancer in patients with ulcerative colitis. Dig Dis Sci (2014) 0.88
5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One (2014) 0.87
Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort. Int J Colorectal Dis (2012) 0.87
Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci (2009) 0.86
Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun? World J Gastroenterol (2009) 0.86
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol (2012) 0.86
Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol (2012) 0.86
Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol (2010) 0.85
Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new? World J Gastrointest Endosc (2012) 0.85
Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol (2012) 0.84
Decreased colorectal cancer and adenoma risk in patients with microscopic colitis. Dig Dis Sci (2011) 0.84
Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis. World J Gastroenterol (2013) 0.84
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol (2011) 0.83
Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer. Inflamm Bowel Dis (2015) 0.83
Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol (2008) 0.83
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol (2012) 0.82
Use of confocal laser endomicroscopy to predict relapse of ulcerative colitis. BMC Gastroenterol (2014) 0.82
Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol (2006) 0.82
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am (2014) 0.82
Backwash ileitis and the risk of colon neoplasia in ulcerative colitis patients undergoing restorative proctocolectomy. Dig Dis Sci (2013) 0.82
Five-aminosalicylic Acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract (2015) 0.81
Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin Cancer Res (2010) 0.81
Strategies for colon cancer prevention. EPMA J (2010) 0.80
Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol (2012) 0.80
Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry. World J Gastroenterol (2013) 0.80
Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. BMC Health Serv Res (2011) 0.79
The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut (2016) 0.78
Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis. Cancers (Basel) (2012) 0.78
The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ. Carcinogenesis (2013) 0.78
Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease. World J Gastroenterol (2013) 0.78
Colorectal Cancer Screening in Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.78
Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Dig Dis Sci (2009) 0.77
Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol (2005) 0.77
Colitis-associated colon cancer: Is it in your genes? World J Gastroenterol (2015) 0.77
Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice. Gut (2014) 0.77
Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines. Cancer Lett (2013) 0.77
In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis. Aliment Pharmacol Ther (2009) 0.77
Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer. Gastrointest Cancer Res (2009) 0.76
PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation. Biochim Biophys Acta (2015) 0.76
Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol (2009) 0.76
Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo. Oncol Lett (2011) 0.76
Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. Drug Des Devel Ther (2011) 0.76
5-ASA Dose-Response: Maximizing Efficacy and Adherence. Gastroenterol Hepatol (N Y) (2010) 0.76
Chemoprevention of colorectal cancer. Dig Dis (2014) 0.76
Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer. Cancer Res Front (2016) 0.76
Macrophage targeting contributes to the inhibitory effects of embelin on colitis-associated cancer. Oncotarget (2016) 0.76
Colorectal Cancer in Inflammatory Bowel Disease: Epidemiology, Pathogenesis and Surveillance. Gastrointest Tumors (2014) 0.76
Cancer Screening and Prevention in Crohn's Disease Patients. Gastroenterol Hepatol (N Y) (2006) 0.75
Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg (2010) 0.75
Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice. J Carcinog (2010) 0.75
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group. Gastroenterol Hepatol (N Y) (2008) 0.75
Simultaneous occurrence of autoimmune pancreatitis and pancreatic cancer in patients resected for focal pancreatic mass. World J Gastroenterol (2017) 0.75
Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis. Drug Des Devel Ther (2013) 0.75
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget (2016) 0.75
Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep (2013) 0.75
New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence. Gastroenterol Hepatol (N Y) (2010) 0.75
Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. Ther Adv Chronic Dis (2010) 0.75
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate. Oncotarget (2016) 0.75
Dysplasia and colitis. Can J Gastroenterol (2009) 0.75
Use of Cancer Stem Cells to Investigate the Pathogenesis of Colitis-associated Cancer. Inflamm Bowel Dis (2016) 0.75
Ulcerative colitis with inflammatory polyposis in a teenage boy: a case report. World J Gastroenterol (2015) 0.75
Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila) (2016) 0.75
Inflammatory Bowel Disease Associated Colorectal Neoplasia. J Gastrointest Dig Syst (2012) 0.75
Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J (2016) 0.75
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease. Clin Exp Gastroenterol (2009) 0.75
Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study. Clin Exp Gastroenterol (2015) 0.75
Advances in the Diagnosis and Management of Colonic Dysplasia in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2017) 0.75
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Colorectal cancer screening: scientific review. JAMA (2003) 4.96
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology (2005) 3.30
Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. Am J Gastroenterol (2005) 2.40
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res (2004) 2.37
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Colorectal cancer screening: clinical applications. JAMA (2003) 1.74
Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience. Dig Dis Sci (2014) 1.50
Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 1.47
Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Dig Dis Sci (2013) 1.42
Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin Cancer Res (2006) 1.28
Promoting use of colorectal cancer screening tests. Can we change physician behavior? J Gen Intern Med (2005) 1.25
Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer (2002) 1.23
Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int J Cancer (2006) 1.23
Surveillance guidelines should be updated to recognize the importance of serrated polyps. Gastroenterology (2010) 1.21
The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer (2002) 1.20
Association of large serrated polyps with synchronous advanced colorectal neoplasia. Am J Gastroenterol (2009) 1.14
Screening for Lynch syndrome: it is time to shift the focus. Dig Dis Sci (2015) 1.10
Early predictors of severe lower gastrointestinal bleeding and adverse outcomes: a prospective study. Clin Gastroenterol Hepatol (2004) 1.09
Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis (2003) 1.09
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis (2012) 1.08
Colorectal cancer screening. J Natl Compr Canc Netw (2013) 1.02
Screening prevalence and incidence of colorectal cancer among American Indian/Alaskan natives in the Indian Health Service. Dig Dis Sci (2011) 0.98
Adaptation of the FLU-FOBT Program for a primary care clinic serving a low-income Chinese American community: new evidence of effectiveness. J Health Care Poor Underserved (2011) 0.96
Colorectal cancer risk perception on the basis of genetic test results in individuals at risk for Lynch syndrome. J Clin Oncol (2009) 0.96
Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res (2005) 0.94
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 0.94
The mechanism of microsatellite instability is different in synchronous and metachronous colorectal cancer. J Gastrointest Surg (2005) 0.92
MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology (2009) 0.90
Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis (2005) 0.89
Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. Best Pract Res Clin Gastroenterol (2003) 0.88
Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 0.86
A comparison of the phenotype and genotype in adenomatous polyposis patients with and without a family history. Fam Cancer (2005) 0.85
Genotype and phenotype of patients with both familial adenomatous polyposis and thyroid carcinoma. Fam Cancer (2003) 0.83
Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci (2011) 0.82
Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events. World J Gastroenterol (2009) 0.82
Tumor histology helps to identify Lynch syndrome among colorectal cancer patients. Fam Cancer (2008) 0.81
Endoscopic management of familial colonic neoplasia. Gastrointest Endosc Clin N Am (2005) 0.81
Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol (2008) 0.80
Hereditary diffuse gastric cancer: surveillance endoscopy is not enough to save lives. Gastroenterology (2007) 0.80
Embarrassment is a major barrier to colon cancer prevention, especially among women: a call to action. Gastroenterology (2006) 0.79
The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven. Am J Gastroenterol (2011) 0.79
Colonoscopy is superior to flexible sigmoidoscopy for colorectal cancer screening: now beyond a reasonable doubt? Gastroenterology (2005) 0.77
Evidence-based analysis: postoperative gastric bleeding: etiology and prevention. Surg Oncol (2003) 0.77
Refining colorectal cancer screening recommendations based on gender. Gastroenterology (2007) 0.76
Screening colonoscopy: the benefits are durable, but are they as great as we thought? Gastroenterology (2006) 0.75
The early use of immunosuppression reduces morbidity in patients with moderately severe or severe Crohn's disease. Gastroenterology (2008) 0.75
"Did you check my colon for flat polyps?" Should patients and colonoscopists really be concerned? Gastroenterology (2008) 0.75
Aspirin curbs colon polyps. But for many, bleeding risks may offset benefits. Health News (2003) 0.75